INTRODUCTION: Early identification of Parkinson's disease (PD) in its prodromal stage has fundamental implications for the future development of neuroprotective therapies. However, no sufficiently accurate biomarkers of prodromal PD are currently available to facilitate early identification. The vocal assessment of patients with isolated rapid eye movement sleep behaviour disorder (iRBD) and PD appears to have intriguing potential as a diagnostic and progressive biomarker of PD and related synucleinopathies. METHODS AND ANALYSIS: Speech patterns in the spontaneous speech of iRBD, early PD and control participants' voice calls will be collected from data acquired via a developed smartphone application over a period of 2 years. A significant increase in several aspects of PD-related speech disorders is expected, and is anticipated to reflect the underlying neurodegeneration processes. ETHICS AND DISSEMINATION: The study has been approved by the Ethics Committee of the General University Hospital in Prague, Czech Republic and all the participants will provide written, informed consent prior to their inclusion in the research. The application satisfies the General Data Protection Regulation law requirements of the European Union. The study findings will be published in peer-reviewed journals and presented at international scientific conferences.

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Prague Czech Republic

See more in PubMed

Poewe W, Seppi K, Tanner CM, et al. . Parkinson disease. Nat Rev Dis Primers 2017;3:17013. 10.1038/nrdp.2017.13 PubMed DOI

de Rijk M, Launer L, Berger K. Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurol 2000;54:S21–3 http://intl.neurology.org/cgi/content/abstract/54/11_suppl_5/S21 PubMed

Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. . Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128–39. 10.1016/S1474-4422(09)70293-5 PubMed DOI

Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 2016;12:622–34. 10.1038/nrneurol.2016.152 PubMed DOI

Postuma RB, Iranzo A, Hu M, et al. . Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019;142:744–59. 10.1093/brain/awz030 PubMed DOI PMC

Boeve BF. REM sleep behavior disorder. Ann N Y Acad Sci 2010;1184:15–54. 10.1111/j.1749-6632.2009.05115.x PubMed DOI PMC

Miglis MG, Adler CH, Antelmi E, et al. . Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol 2021;20:671–84. 10.1016/S1474-4422(21)00176-9 PubMed DOI PMC

Iranzo A, Tolosa E, Gelpi E, et al. . Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12:443–53. 10.1016/S1474-4422(13)70056-5 PubMed DOI

Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013;14:744–8. 10.1016/j.sleep.2012.10.009 PubMed DOI

Schenck CH, Montplaisir JY, Frauscher B, et al. . Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013;14:795–806. 10.1016/j.sleep.2013.02.016 PubMed DOI PMC

Postuma RB, Aarsland D, Barone P, et al. . Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617–26. 10.1002/mds.24996 PubMed DOI

Duffy J. Motor speech disorders: substrates, differential diagnosis, and management. Fourth ed. Maryland Heights: Elsevier, 2019.

Ho AK, Iansek R, Marigliani C, et al. . Speech impairment in a large sample of patients with Parkinson's disease. Behav Neurol 1999;11:131–7. 10.1155/1999/327643 PubMed DOI

Rusz J, Hlavnička J, Novotný M, et al. . Speech biomarkers in rapid eye movement sleep behavior disorder and Parkinson disease. Ann Neurol 2021;90:62–75. 10.1002/ana.26085 PubMed DOI PMC

Rusz J, Hlavnicka J, Tykalova T, et al. . Smartphone allows capture of speech abnormalities associated with high risk of developing Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng 2018;26:1495–507. 10.1109/TNSRE.2018.2851787 PubMed DOI

Goetz CG, Tilley BC, Shaftman SR, et al. . Movement disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and Clinimetric testing results. Mov Disord 2008;23:2129–70. 10.1002/mds.22340 PubMed DOI

Arora S, Venkataraman V, Zhan A, et al. . Detecting and monitoring the symptoms of Parkinson's disease using smartphones: a pilot study. Parkinsonism Relat Disord 2015;21:650–3. 10.1016/j.parkreldis.2015.02.026 PubMed DOI

Espay AJ, Bonato P, Nahab FB, et al. . Technology in Parkinson's disease: challenges and opportunities. Mov Disord 2016;31:1272–82. 10.1002/mds.26642 PubMed DOI PMC

Artusi CA, Mishra M, Latimer P, et al. . Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. Parkinsonism Relat Disord 2018;46 Suppl 1:S53–6. 10.1016/j.parkreldis.2017.07.022 PubMed DOI PMC

Zhan A, Mohan S, Tarolli C, et al. . Using Smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score. JAMA Neurol 2018;75:876–80. 10.1001/jamaneurol.2018.0809 PubMed DOI PMC

Lipsmeier F, Taylor KI, Kilchenmann T, et al. . Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Mov Disord 2018;33:1287–97. 10.1002/mds.27376 PubMed DOI PMC

Arora S, Baig F, Lo C, et al. . Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD. Neurology 2018;91:e1528–38. 10.1212/WNL.0000000000006366 PubMed DOI PMC

Rusz J, Tykalova T, Ramig LO, et al. . Guidelines for speech recording and acoustic analyses in Dysarthrias of movement disorders. Mov Disord 2021;36:803–14. 10.1002/mds.28465 PubMed DOI

Povey D, Ghoshal A, Boulianne G. The Kaldi speech recognition toolkit. Proc IEEE Workshop Autom Speech Recognit Underst, 2011.

Schultz T, Vu N, Schlippe T. GlobalPhone: A multilingual text & speech database in 20 languages. In: 2013 Proc IEEE Int Conf Acoust Speech Signal Process, 2013: 8126–30.

Martin R. Noise power spectral density estimation based on optimal smoothing and minimum statistics. IEEE Trans. Speech Audio Process. 2001;9:504–12. 10.1109/89.928915 DOI

Illner V, Sovka P, Rusz J. Validation of freely-available pitch detection algorithms across various noise levels in assessing speech captured by smartphone in Parkinson’s disease. Biomed Signal Process Control 2020;58:101831. 10.1016/j.bspc.2019.101831 DOI

Ho AK, Iansek R, Marigliani C, et al. . Speech impairment in a large sample of patients with Parkinson's disease. Behav Neurol 1999;11:131–7. PubMed

Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J Speech Hear Res 1969;12:246–69. 10.1044/jshr.1202.246 PubMed DOI

Jannetts S, Lowit A. Cepstral analysis of hypokinetic and ataxic voices: correlations with perceptual and other acoustic measures. J Voice 2014;28:673–80. 10.1016/j.jvoice.2014.01.013 PubMed DOI

Rusz J, Cmejla R, Tykalova T, et al. . Imprecise vowel articulation as a potential early marker of Parkinson's disease: effect of speaking task. J Acoust Soc Am 2013;134:2171–81. 10.1121/1.4816541 PubMed DOI

Hlavnička J, Čmejla R, Tykalová T, et al. . Automated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorder. Sci Rep 2017;7:12. 10.1038/s41598-017-00047-5 PubMed DOI PMC

Beltrami D, Gagliardi G, Rossini Favretti R, et al. . Speech analysis by natural language processing techniques: a possible tool for very early detection of cognitive decline? Front Aging Neurosci 2018;10:369. 10.3389/fnagi.2018.00369 PubMed DOI PMC

Laganas C, Iakovakis D, Hadjidimitriou S. Parkinson’s Disease Detection Based on Running Speech Data From Phone Calls. IEEE Trans Biomed Eng 2021 PubMed

Rusz J, Cmejla R, Ruzickova H, et al. . Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson's disease. J Acoust Soc Am 2011;129:350–67. 10.1121/1.3514381 PubMed DOI

Novotny M, Rusz J, Cmejla R. Automatic Evaluation of Articulatory Disorders in Parkinson’s Disease. IEEE/ACM Trans Audio Speech Lang Process 2014;22:1366–78.

American Academy of Sleep Medicine . International Classification of Sleep Disorders. In: Diagnostic and coding manual. Third ed. Chicago, Illinois: American Academy of Sleep Medicine, 2014.

Postuma RB, Berg D, Stern M, et al. . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–601. 10.1002/mds.26424 PubMed DOI

Nasreddine ZS, Phillips NA, Bédirian V, et al. . The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–9. 10.1111/j.1532-5415.2005.53221.x PubMed DOI

Visser M, Marinus J, Stiggelbout AM, et al. . Assessment of autonomic dysfunction in Parkinson’s disease: The SCOPA-AUT. Mov Disord. 2004;19:1306–12. 10.1002/mds.20153 PubMed DOI

Beck A, Steer R, Brown G. Manual for the Beck depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.

Paolini Paoletti F, Gaetani L, Parnetti L. The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers. Biomolecules 2020;10:335. 10.3390/biom10020335 PubMed DOI PMC

Espay AJ, Schwarzschild MA, Tanner CM, et al. . Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials. Mov Disord 2017;32:319–24. 10.1002/mds.26913 PubMed DOI PMC